2026-11-19 マウントサイナイ医療システム(MSHS)
<関連情報>
- https://www.mountsinai.org/about/newsroom/2026/mount-sinai-researchers-identify-a-shared-molecular-weakness-in-glioblastoma-tumor-cells-that-may-offer-a-new-treatment-target
- https://www.cell.com/neuron/abstract/S0896-6273(26)00808-1
神経膠芽腫ではグリア前駆細胞様状態が選択的に利用され、POU3F3によって維持される
Glial progenitor-like state is preferentially co-opted in glioblastoma and sustained by POU3F3
Susana I. Ramos, Mohammad Imran K. Khan, Wan Sze Cheng, Balagopal Pai, Thenzing J. Silva-Hurtado, Jorge Samanamud, Xi Chen, Kristin G. Beaumont, Robert P. Sebra, Raymund L. Yong, Timothy E. Richardson, Amanda Krausert, Lakshmi S.K. Mahadevan, Elena Zaslavsky, Nadejda M. Tsankova
Neuron(2026年11月11日オンライン公開)Article type:NeuroResource
DOI:https://doi.org/10.1016/j.neuron.2026.10.012
Glioblastoma (GBM) is an aggressive brain tumor in which oncofetal reprogramming, the reactivation of developmental cellular programs, may contribute to tumor growth and recurrence. To investigate this process, the researchers generated an expanded human spatiotemporal multi-omic dataset that resolves neurogenic and gliogenic lineage development. They compared tumor cores and infiltrative margins from primary and recurrent GBM samples. The analyses revealed preferential enrichment of a glial intermediate progenitor cell (gIPC)-like state across tumor regions and recurrent disease. This state most closely resembled gIPCs found in the third-trimester germinal matrix during human brain development. The researchers identified EGFR and the long non-coding RNA NRXN1-DT as characteristic markers of this progenitor-like state and demonstrated the potential clinical utility of NRXN1-DT in GBM diagnostics. They further identified the transcription factor POU3F3 as a key regulator that controls NRXN1-DT enhancer activity and EGFR expression while maintaining GBM stem/progenitor-like properties. These findings reveal how developmental glial programs are co-opted during glioblastoma progression and provide a foundation for investigating POU3F3 and other gliogenic regulators as potential therapeutic targets. Further studies are needed to determine whether targeting these pathways can effectively suppress tumor growth and recurrence.原著論文:Cell Press – Neuron


